Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
- Conditions
- Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Mesoblast International Sàrl
- Registration Number
- NCT04456439
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
- Conditions
- Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Mesoblast International Sàrl
- Registration Number
- NCT04366830
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy
- Conditions
- Recovery Following Partial Medial Meniscectomy
- Interventions
- Drug: ChondrogenDrug: Placebo
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Mesoblast International Sàrl
- Target Recruit Count
- 55
- Registration Number
- NCT00702741
- Locations
- 🇺🇸
University of Southern California Keck School of Medicine, Los Angeles, California, United States
🇺🇸OrthoIndy, Indianapolis, Indiana, United States
🇺🇸TRIA Orthopaedic Center, Bloomington, Minnesota, United States
A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy
- Conditions
- Recovery Following Partial Medial Meniscectomy
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Mesoblast International Sàrl
- Target Recruit Count
- 60
- Registration Number
- NCT00225095
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Orthopedic Center of Vero Beach, Vero Beach, Florida, United States
🇺🇸Midwest Orthopaedics at Rush, Chicago, Illinois, United States
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
- Conditions
- Myelodysplastic SyndromesGraft Versus Host DiseaseLeukemia
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Mesoblast International Sàrl
- Registration Number
- NCT00081055
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States